PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33668509-3	2021	Several mutant IDH inhibitors are currently in clinical trials, including AG-881 and BAY-1436032.	BAY 1436032	85-96	isocitrate dehydrogenase (NADP(+)) 1	Homo sapiens	15-18	
33622704-0	2021	Phase I assessment of safety and therapeutic activity of BAY1436032 in patients with IDH1-mutant solid tumors.	BAY 1436032	57-67	isocitrate dehydrogenase (NADP(+)) 1	Homo sapiens	85-89	
33622704-1	2021	PURPOSE: BAY1436032, an inhibitor of mutant isocitrate dehydrogenase 1 (mIDH1), was active against multiple IDH1-R132X solid tumors in preclinical models.	BAY 1436032	9-19	isocitrate dehydrogenase (NADP(+)) 1	Homo sapiens	73-77	
32241846-0	2021	Synergistic activity of IDH1 inhibitor BAY1436032 with azacitidine in IDH1 mutant acute myeloid leukemia.	BAY 1436032	39-49	isocitrate dehydrogenase (NADP(+)) 1	Homo sapiens	24-28	
32241846-0	2021	Synergistic activity of IDH1 inhibitor BAY1436032 with azacitidine in IDH1 mutant acute myeloid leukemia.	BAY 1436032	39-49	isocitrate dehydrogenase (NADP(+)) 1	Homo sapiens	70-74	
32733012-0	2020	Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study results.	BAY 1436032	23-33	isocitrate dehydrogenase (NADP(+)) 1	Homo sapiens	37-41	
32733012-1	2020	The mutant IDH1 (mIDH1) inhibitor BAY1436032 demonstrated robust activity in preclinical AML models, supporting clinical evaluation.	BAY 1436032	34-44	isocitrate dehydrogenase (NADP(+)) 1	Homo sapiens	11-15	
28232670-0	2017	Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo.	BAY 1436032	26-36	isocitrate dehydrogenase (NADP(+)) 1	Homo sapiens	11-15	
28232670-0	2017	Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo.	BAY 1436032	26-36	isocitrate dehydrogenase (NADP(+)) 1	Homo sapiens	71-75	
28232670-2	2017	Here we report the characterization of BAY1436032, a novel pan-mutant IDH1 inhibitor, both in vitro and in vivo.	BAY 1436032	39-49	isocitrate dehydrogenase (NADP(+)) 1	Homo sapiens	70-74	
28232670-5	2017	Oral administration of BAY1436032 led to leukemic blast clearance, myeloid differentiation, depletion of leukemic stem cells and prolonged survival in two independent patient-derived xenograft IDH1 mutant AML mouse models.	BAY 1436032	23-33	isocitrate dehydrogenase (NADP(+)) 1	Homo sapiens	193-197	
28232670-6	2017	Together, BAY1436032 is highly effective against all major types of IDH1 mutant AML.	BAY 1436032	10-20	isocitrate dehydrogenase (NADP(+)) 1	Homo sapiens	68-72	
28124097-0	2017	Pan-mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma in vivo.	BAY 1436032	26-37	isocitrate dehydrogenase (NADP(+)) 1	Homo sapiens	11-15	
28124097-0	2017	Pan-mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma in vivo.	BAY 1436032	26-37	isocitrate dehydrogenase (NADP(+)) 1	Homo sapiens	65-69	
28124097-4	2017	Here, we describe the development and properties of BAY 1436032, a pan-inhibitor of IDH1 protein with different codon 132 mutations.	BAY 1436032	52-63	isocitrate dehydrogenase (NADP(+)) 1	Homo sapiens	84-88	
28124097-5	2017	BAY 1436032 strongly reduces 2-HG levels in cells carrying IDH1-R132H, -R132C, -R132G, -R132S and -R132L mutations.	BAY 1436032	0-11	isocitrate dehydrogenase (NADP(+)) 1	Homo sapiens	59-63